NBIX
NBIX
US64125C1099
Neurocrine Biosciences, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 100/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±33.1% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).

Beta (Market Relation)
0.4x
Defensive
Volatility (5Y p.a.)
33.1% p.a.
5-Year Horizon
Max Drawdown (5Y)
-42.9%
5-Year Horizon
Sharpe Ratio
0.11
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +1.6%
3 Years 34.2% -42.9% 0.15 +7.7%
5 Years 33.1% -42.9% 0.11 +6.3%
10 Years 39.0% -46.4% 0.24 +11.7%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (33.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -46.4% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
2 ISS Score: 2 / 10
Audit Risk
3 ISS Score: 3 / 10
Board Risk
2 ISS Score: 2 / 10
Short Ratio
4.85
ende